Cytosorbents (CTSO) EPS (Weighted Average and Diluted) Growth (1y) (2016 - 2026)
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Weighted Avg. Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 152.82 Bn | 146.17 Bn | 6.27 Bn | -19.74% |
| 2 | Stryker | 115.07 Bn | 112.19 Bn | 3.81 Bn | 14.20% |
| 3 | Medtronic | 95.25 Bn | 87.08 Bn | 5.76 Bn | -11.88% |
| 4 | Boston Scientific | 71.38 Bn | 70.17 Bn | 3.61 Bn | 100.00% |
| 5 | Edwards Lifesciences | 51.08 Bn | 47.41 Bn | 1.29 Bn | 8.20% |
| 6 | Koninklijke Philips | 29.38 Bn | 26.07 Bn | 2.07 Bn | - |
| 7 | Dexcom | 28.84 Bn | 27.72 Bn | 750.30 Mn | 88.89% |
| 8 | GE HealthCare Technologies | 28.56 Bn | 26.49 Bn | 1.98 Bn | -30.89% |
| 9 | Steris | 20.71 Bn | 20.30 Bn | 697.10 Mn | 47.37% |
| 10 | Cytosorbents | 28.81 Mn | 24.01 Mn | 6.13 Mn | -300.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -300.00% |
| Dec 31, 2025 | 35.71% |
| Sep 30, 2025 | 0.00% |
| Jun 30, 2025 | 137.50% |
| Mar 31, 2025 | 81.82% |
| Dec 31, 2024 | -16.67% |
| Sep 30, 2024 | 76.19% |
| Jun 30, 2024 | 46.67% |
| Mar 31, 2024 | 35.29% |
| Dec 31, 2023 | -500.00% |
| Sep 30, 2023 | 25.00% |
| Jun 30, 2023 | 40.00% |
| Mar 31, 2023 | 19.05% |
| Dec 31, 2022 | 92.00% |
| Sep 30, 2022 | -86.67% |
| Jun 30, 2022 | -127.27% |
| Mar 31, 2022 | -110.00% |
| Dec 31, 2021 | -1,331.96% |
| Sep 30, 2021 | -650.00% |
| Jun 30, 2021 | -37.50% |
| Mar 31, 2021 | 0.00% |
| Dec 31, 2020 | 86.57% |
| Sep 30, 2020 | 90.48% |
| Jun 30, 2020 | 27.27% |
| Mar 31, 2020 | 33.33% |
| Jun 30, 2016 | -340.00% |